Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K⁺ channel

Mine S. Cicek¹, Devin C. Koestler⁶, Brooke L. Fridley⁷, Kimberly R. Kalli², Sebastian M. Armasu¹, Melissa C. Larson¹, Chen Wang¹, Stacey J. Winham¹, Robert A. Vierkant¹, David N. Rider¹, Matthew S. Block³, Brandy Klotzle⁹, Gottfried Konecny¹⁰, Boris J. Winterhoff⁴, Habib Hamidi¹⁰, Viji Shridhar⁵, Jian-Bing Fan⁹, Daniel W. Visscher⁵, Janet E. Olson¹, Lynn C. Hartmann³, Marina Bibikova⁹, Jeremy Chien⁸, Julie M. Cunningham⁵ and Ellen L. Goode¹*,

¹Department of Health Sciences Research, ²Department of Medicine, ³Department of Oncology, ⁴Department of Obstetrics and Gynecology and ⁵Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA, ⁶Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth College, Lebanon, NH 03756, USA, ⁷Department of Biostatistics and ⁸Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA, ⁹Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA and ¹⁰Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90404, USA

Received October 9, 2012; Revised March 24, 2013; Accepted April 2, 2013

Ovarian cancer remains the leading cause of death in women with gynecologic malignancies, despite surgical advances and the development of more effective chemotherapeutics. As increasing evidence indicates that clear-cell ovarian cancer may have unique pathogenesis, further understanding of molecular features may enable us to begin to understand the underlying biology and histology-specific information for improved outcomes. To study epigenetics in clear-cell ovarian cancer, fresh frozen tumor DNA (n = 485) was assayed on Illumina Infinium HumanMethylation450 BeadChips. We identified a clear-cell ovarian cancer tumor methylation profile (n = 163) which we validated in two independent replication sets (set 1, n = 163; set 2, n = 159), highlighting 22 CpG loci associated with nine genes (VWA1, FOXP1, FGFR1, LINC00340, KCNH2, ANK1, ATXN2, NDRG21 and SLC16A11). Nearly all of the differentially methylated CpGs showed a propensity toward hyper-methylation among clear-cell cases. Several loci methylation inversely correlated with tumor gene expression, most notably KCNH2 (HERG, a potassium channel) (P = 9.5 × 10⁻⁷), indicating epigenetic silencing. In addition, a predicted methylation class mainly represented by the clear-cell cases (20 clear cell out of 23 cases) had improved survival time. Although these analyses included only 30 clear-cell carcinomas, results suggest that loss of expression of KCNH2 (HERG) by methylation could be a good prognostic marker, given that over-expression of the potassium (K⁺) channel Eag family members promotes increased proliferation and results in poor prognosis. Validation in a bigger cohort of clear-cell tumors of the ovary is warranted.

INTRODUCTION

Clear-cell ovarian cancer cases are known to be associated with endometriosis, diagnosed at younger age and lower stage, have lower frequency of BRCA1 and BRCA2 mutations and higher frequency of ARID1A and PIK3CA mutations and have greater resistance for first-line platinum and taxane-based chemotherapy and poorer survival in advanced stages than

*To whom correspondence should be addressed. Tel: +1 5072667997; Fax: +1 5072662478; Email egoode@mayo.edu

© The Author 2013. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
other subtypes (1,2). Clear-cell subtype is one of the most common subtypes of ovarian cancer: high-grade serous (70%), low-grade serous (5%), endometrioid (10%), clear cell (10%) and mucinous (3%) (3). The current standard of care for the treatment is surgical resection (debulking) followed by adjuvant chemotherapy (4,5). Despite advances in surgical technologies and the development of more effective chemotherapeutics, epithelial ovarian cancer (EOC) remains the leading cause of death in women with gynecologic malignancies (6).

At present, ovarian cancer is clinically considered as a single disease, and treatment is dependent upon tumor stage and grade rather than histology. However, the increasing evidence indicates that clear-cell ovarian cancer has a different etiology, clinical characteristics and outcomes that are distinct from the other histological subtypes (1,7–9). Given our current knowledge, ovarian clear-cell carcinoma is distinct from other ovarian cancer histologies and warrants identification of molecular features to understand its biology, as further understanding of this disease may enable subtype-specific treatment options to improve patient outcomes. Thus far, efforts in distinguishing clear-cell from other ovarian cancer have been based on gene expression analysis showing gene expression patterns reflecting both morphological features and biological behavior (10).

DNA methylation, predominantly of cytosine residues adjacent to guanine bases (i.e. CpG dinucleotides), is a key epigenetic process involved in the regulation of gene expression across a variety of cellular processes, including genomic imprinting, chromosome X inactivation and chromosomal integrity (11,12). Dysregulation of DNA methylation is associated with multiple human diseases including cancer (13), and there is a growing interest in the role of DNA methylation in carcinogenesis and tumorigenesis and the use of such information for differentiating cancer subtypes at a molecular level. In an effort to identify molecular alterations, several epigenomic studies examining tumor DNA methylation have been conducted in ovarian cancer; however, these studies were not genome-wide, or they focused on only the high-grade serous subtype (14–18). Thus, more comprehensive studies involving epigenome-wide assessment of DNA methylation are needed to fully understand ovarian clear-cell cancer. Here, in order to begin to understand the underlying biology unique to clear-cell ovarian cancer, we examined the hypothesis that the ovarian cancer clear-cell subtype has a distinct tumor methylation profile from other subtypes that also is associated with epigenetic silencing. Assessing over 485 000 CpG sites in a total of 485 ovarian cancer cases including 30 clear-cell carcinomas, the present study represents the most comprehensive study to date of tumor DNA methylation in the context of ovarian cancer.

RESULTS

Methylation clustering

An ovarian cancer tumor DNA methylation profile associated with clear-cell histology was identified and validated using three roughly equally sized collections, including one training data set (n = 163) and two independent replication data sets (set 1, n = 163; set 2, n = 159). Characteristics of the Mayo Clinic cases studied (n = 485) are shown in Table 1 and reflect the expected distributions of clinical features and similarity across analytical sets. A Gaussian distributed recursively partitioned mixture model (RPMM) was fit to the training data set to cluster ovarian cancer cases using the logit-transformed methylation beta values for the CpG loci most strongly associated with clear-cell histology. The optimal number of markers, M, was found to be 22 based on a nested cross-validation procedure (Supplementary Material, Figure S1); thus, the top 22 CpG loci were selected in the training set as the basis of the clear-cell-specific methylation profile (Table 2).

The clustering of the training set of samples using these 22 CpG loci resulted in 8 methylation classes, delineated as right branch R of the dendrogram (RL1, RLR, RRL, RRR) and left branch L of the dendrogram (LLL, LLR, LRL, LRR). Several of the 22 most discriminatory CpGs reside in close proximity (e.g. those on chromosomes 4, 7, 8, 14, 17 and X). Therefore,

<table>
<thead>
<tr>
<th>Table 1. Characteristics of study participants, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Site</strong></td>
</tr>
<tr>
<td>Ovarian 155 (95)</td>
</tr>
<tr>
<td>Fallopian tube 6 (4)</td>
</tr>
<tr>
<td>Primary peritoneal 2 (1)</td>
</tr>
<tr>
<td><strong>Histology</strong></td>
</tr>
<tr>
<td>High-grade serous 115 (71)</td>
</tr>
<tr>
<td>Low-grade serous 7 (4)</td>
</tr>
<tr>
<td>Endometrioid 27 (17)</td>
</tr>
<tr>
<td>Clear cell 9 (6)</td>
</tr>
<tr>
<td>Mucinous 4 (2)</td>
</tr>
<tr>
<td>Serous, grade unknown 2 (1)</td>
</tr>
<tr>
<td><strong>Age at diagnosis, years</strong></td>
</tr>
<tr>
<td>Median (range) 61 (28–85)</td>
</tr>
<tr>
<td><strong>Stage</strong></td>
</tr>
<tr>
<td>Stage 1 20 (12)</td>
</tr>
<tr>
<td>Stage 2 9 (6)</td>
</tr>
<tr>
<td>Stage 3 102 (63)</td>
</tr>
<tr>
<td>Stage 4 32 (20)</td>
</tr>
<tr>
<td><strong>Grade</strong></td>
</tr>
<tr>
<td>Low grade 24 (15)</td>
</tr>
<tr>
<td>High grade 138 (85)</td>
</tr>
<tr>
<td>Unknown 1</td>
</tr>
<tr>
<td><strong>Ascites</strong></td>
</tr>
<tr>
<td>Yes 93 (70)</td>
</tr>
<tr>
<td>No 40 (30)</td>
</tr>
<tr>
<td>Unknown 30</td>
</tr>
<tr>
<td><strong>Surgical debulking status</strong></td>
</tr>
<tr>
<td>Optimal (&lt;1 cm) 133 (83)</td>
</tr>
<tr>
<td>Sub-optimal (≥1 cm) 27 (17)</td>
</tr>
<tr>
<td>Unknown 3</td>
</tr>
<tr>
<td><strong>Peritoneal cytology</strong></td>
</tr>
<tr>
<td>Positive 126 (84)</td>
</tr>
<tr>
<td>Negative 24 (16)</td>
</tr>
<tr>
<td>Unknown 13</td>
</tr>
</tbody>
</table>

Numbers are n (%) unless otherwise specified.
methylation beta values are likely to be highly correlated (19,20), representing essentially 11 ‘blocks’ of differential methylation. All but three of these ‘blocks’ were located in CpG islands or shores (flanking regions 0–2 kb from CpG islands), and all but two of these ‘blocks’ were in a known gene. Nine genes associated with the CpGs identified in this analysis included VWA1 (von Willebrand factor A domain containing 1), FOXP1 (forkhead box P1), FGFRL1 (fibroblast growth factor receptor-like 1), KCNH2 [potassium voltage-gated channel, subfamily H (eag-related), member 2], ANK1 (ankyrin 1, erythrocytic), ATXN2 (ataxin 2), NDRG21 (NDRG family member 2) and SLC16A11 [solute carrier family 16, member 11 (monocarboxylic acid transporter 11)]; (Table 2).

The semi-supervised RPMM (SS-RPMM) solution fit to the training data set based on the profile determined using the 22 CpG loci was then used to predict methylation class membership in two independent replication data sets. In the first replication set, methylation right branch (R) classes (those beginning with R) included 12 cases and were significantly enriched for clear-cell cases compared with L classes (those beginning with L), which were devoid of clear-cell cases (permutation chi-square $P < 1 \times 10^{-16}$). Further, the RRL class contained all of the clear-cell cases ($n = 8$) as well as one serous and one mucinous case (Fig. 1A). At most loci, clear-cell tumors were hypermethylated compared with other histologies; however, at the loci on chromosomes 3 and 12 (cg15958828 in FOXP1, and cg07058694 in ATXN2, respectively), hypomethylation in clear-cell tumors was observed (Table 2).

Similar results were seen in the analysis of the second replication data set, which consisted of 159 cases, including 13 of clear-cell histology. The clear-cell methylation profile again provided good prediction for clear-cell tumors; the R class included a greater proportion of clear-cell cases than the L class ($P < 7.8 \times 10^{-6}$), and the RRL class again contained the majority of the clear-cell cases (Fig. 1B). Unlike in the first replication set, some clear-cell cases were assigned to other classes, with four in the LRR classes and one in the RRL classes. The patterns of methylation by subtype were similar to those in the first replication data set (Table 2).

As expected, the correlation between methylation beta values among the 22 CpGs was high for CpGs in close proximity (Pearson’s correlation coefficient $> 0.62$), namely ‘blocks’ of CpGs, as mentioned earlier, on chromosomes 4, 7, 8, 14, 17 and X. As shown in Supplementary Material, Figure S2, correlation patterns were similar in both replication sets. The two loci showing clear-cell hypomethylation (cg15958828 in FOXP1 on chromosome 3 and cg07058694 in ATXN2 on chromosome 12) were correlated with each other (Pearson’s correlation coefficient $= 0.84$) and negatively correlated with the other loci.

### Correlation of methylation with gene expression

Promoter-associated CpGs are generally thought to be unmethylated (21); however, hypermethylation of CpG island loci may be associated with the modification of gene activation, especially gene silencing (22,23). Therefore, cis association between expression and methylation was examined ($n = 171$)
for the 22 CpG loci (Supplementary Material, Table S1), of which 59% \((n = 13)\) were located in CpG island regions. A total of 18 transcripts from nine genes were investigated \((VWA1, \text{FOXP1, FGFRL1, LINC00340, KCNH2, ANK1, ATXN2, NDRG2 and SLC16A11}\) containing CpGs). Since many of the 22 CpGs were located in CpG islands, we observed an expected inverse relationship between methylation and expression given the well-established role of CpG island hypermethylation on repression of gene expression. The strongest relationship between hypermethylation and reduced mRNA expression was at \(\text{KCNH2}\) on chromosome 7 with cg15472092 in a CpG island \((\text{Spearman’s correlation} = -0.37, \text{\(P = 9.5 \times 10^{-7}\)}); consistent results were seen at related \(\text{KCNH2}\) CpGs and probes. The gene expression was reduced in clear-cell cases compared with non-clear-cell cases measured with two \(\text{KCNH2}\) expression probes, A_23_P377882 \((\text{\(P = 6.5 \times 10^{-4}\)}\)) and A_23_P168403 \((\text{\(P = 0.04\)}\)). Although, methylation on chromosome 8 \((\text{cg13152952})\), located \(>4\) kb from the nearest CpG island, was associated with increased expression of \(\text{ANK1}\) \((\text{Spearman’s correlation} = 0.27, \text{\(P = 3.4 \times 10^{-4}\)}), which might be expected, as the CpG site was not in a CpG island. Modest associations were seen at \(\text{VWA1, NDRG2, SLC25A29}\); at other loci, strong cis associations were generally not observed (Table 3).

**Pathway analysis**

We further evaluated robustness of our model by increasing the number of selected top CpG probes from 22 to 100 in the training set. Clustering results always showed significant consistency with our optimal model using 22 CpGs even when we increased the number of top CpGs to 100 or even more (data not shown). This overall consistency enabled us to include more probes (genes) in an exploratory pathway analysis with the goal of examining the relationships between clear-cell histology and molecular functions of genes associated with differentially methylated CpGs. We chose to use the top 100 CpGs for the pathway analysis. For the 54 genes which included these 100 top CpGs, a function group entitled ‘Differentiation of Cells’ appeared to be over-represented.
Table 3. Correlation between clear-cell CpG loci and cis gene expression (n = 171)

<table>
<thead>
<tr>
<th>CpG</th>
<th>Chr</th>
<th>Position</th>
<th>Gene</th>
<th>Expression probe</th>
<th>Expression probe genomic coordinates</th>
<th>Spearman’s correlation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>cg06444575</td>
<td>1</td>
<td>1369772</td>
<td>VWA1</td>
<td>A_23_P96089</td>
<td>1376065—1376124</td>
<td>−0.23</td>
<td>0.002</td>
</tr>
<tr>
<td>cg15958828</td>
<td>3</td>
<td>71598380</td>
<td>FOXP1</td>
<td>A_24_P362737</td>
<td>71006080—71006021</td>
<td>−0.05</td>
<td>0.51</td>
</tr>
<tr>
<td>cg17105609</td>
<td>4</td>
<td>1006237</td>
<td>FGFR1L</td>
<td>A_24_P46212</td>
<td>1018729—1018788</td>
<td>0.04</td>
<td>0.63</td>
</tr>
<tr>
<td>cg08774969</td>
<td>4</td>
<td>1006240</td>
<td>FGFR1L</td>
<td>A_24_P46212</td>
<td>1018729—1018788</td>
<td>−0.15</td>
<td>0.06</td>
</tr>
<tr>
<td>cg05866411</td>
<td>4</td>
<td>1006278</td>
<td>FGFR1L</td>
<td>A_24_P46212</td>
<td>1018729—1018788</td>
<td>−0.04</td>
<td>0.65</td>
</tr>
<tr>
<td>cg00641409</td>
<td>6</td>
<td>21666778</td>
<td>LINCO00340</td>
<td>A_24_P838448</td>
<td>22194466—22194525</td>
<td>0.08</td>
<td>0.27</td>
</tr>
<tr>
<td>cg18423852</td>
<td>7</td>
<td>150653001</td>
<td>KCNH2</td>
<td>A_23_P168403</td>
<td>150642151—150642092</td>
<td>−0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>cg15472092</td>
<td>7</td>
<td>150653079</td>
<td>KCNH2</td>
<td>A_23_P377882</td>
<td>150647043—150646984</td>
<td>0.03</td>
<td>0.68</td>
</tr>
<tr>
<td>cg18296036</td>
<td>7</td>
<td>150653115</td>
<td>KCNH2</td>
<td>A_23_P168403</td>
<td>150642151—150642092</td>
<td>−0.17</td>
<td>0.03</td>
</tr>
<tr>
<td>cg13152952</td>
<td>8</td>
<td>41570554</td>
<td>ANK1</td>
<td>A_24_P162483</td>
<td>41512136—41512077</td>
<td>0.18</td>
<td>0.02</td>
</tr>
<tr>
<td>cg10601625</td>
<td>8</td>
<td>41570622</td>
<td>ANK1</td>
<td>A_24_P162485</td>
<td>41512299—41512240</td>
<td>0.27</td>
<td>3.4 × 10−4</td>
</tr>
<tr>
<td>cg07058694</td>
<td>12</td>
<td>111909145</td>
<td>ATXN2</td>
<td>A_23_P389907</td>
<td>111890389—111890330</td>
<td>0.00</td>
<td>0.99</td>
</tr>
<tr>
<td>cg01574694</td>
<td>14</td>
<td>21493664</td>
<td>NDRG2</td>
<td>A_23_P37205</td>
<td>21485133—21485074</td>
<td>−0.21</td>
<td>0.005</td>
</tr>
<tr>
<td>cg05940703</td>
<td>17</td>
<td>6947032</td>
<td>SLC16A11</td>
<td>A_23_P363313</td>
<td>6945224—6945165</td>
<td>0.02</td>
<td>0.08</td>
</tr>
<tr>
<td>cg15639045</td>
<td>17</td>
<td>6947200</td>
<td>SLC16A11</td>
<td>A_23_P363313</td>
<td>6945224—6945165</td>
<td>−0.16</td>
<td>0.06</td>
</tr>
<tr>
<td>cg03892045</td>
<td>17</td>
<td>6947288</td>
<td>SLC16A11</td>
<td>A_23_P363313</td>
<td>6945224—6945165</td>
<td>−0.25</td>
<td>9.3 × 10−4</td>
</tr>
<tr>
<td>cg03712541</td>
<td>17</td>
<td>6947294</td>
<td>SLC16A11</td>
<td>A_23_P363313</td>
<td>6945224—6945165</td>
<td>0.01</td>
<td>0.45</td>
</tr>
</tbody>
</table>

Chr, chromosome; build 37. Relationship to a canonical CpG island: shores—0—2 kb from a CpG island; shelves—2—4 kb from a CpG island; methylation probes are annotated within a gene (CpGs that are not located in a gene were excluded from this analysis; cg10963192, cg15869718, cg18139254 on chromosome 14, and cg13976265, cg04174838 on chromosome X); horizontal lines indicate positionally grouped CpG ‘blocks’.

(P = 8.6 × 10−3), including genes ADK, ATXN2, COL11A2, FOXP1, NCO2, NES, NFIB, PCSK2, PO2F2, TGFBI, TGFBI11 and WNT4. Network analysis identified three biological networks (i.e. a group of biologically related genes), which included 10 or more of the CpG-containing genes. These biological networks were ‘Developmental Disorder, Cell Death, Renal Necrosis/Cell Death’, ‘Cellular Assembly and Organization, Neurological Disease, Organismal Injury and Abnormalities’ and ‘Cell Cycle, Cellular Development, Cell Death’. The last network included the largest number of these genes (n = 19; ADK, ANK1, COL11A2, CYTH3, EXOC2, FGFR1L, FOXP1, KCNH2, NCO2, NDRG2, NES, NFIB, PCSK2, PO2F2, PROC, TGFBI, TGFBI11, TRIB1 and WNT4) and is displayed in Supplementary Material, Figure S3.

Association with overall survival

Survival time did not differ in clear-cell cases (n = 30, including 20 RRL cases) compared with other histologies (P = 0.55) (Supplementary Material, Figure S4A); however, cases in the predicted RRL methylation class (n = 23, including 20 clear-cell cases) showed a trend in improved survival time compared with other methylation classes (P = 0.08; Supplementary Material, Figure S4B). Thus, reclassification of only 13 cases based on predicted methylation class accounts for this difference. The survival analysis should be validated with a replication study on independent set of cases. This exploratory analysis suggests that the clear-cell-associated methylation profile, in particular the RRL class, may, in fact, differentiate a novel clinically relevant subgroup and more precisely predict long-term survival prognosis.

**DISCUSSION**

Ovarian cancer is the leading cause of death in women with gynecologic malignancies; its current treatment scheme is solely dependent on stage and grade of the disease. The different histological subtypes which exhibit distinct clinical and genetic features warrant further research in an effort to...
understand the biology of ovarian cancer (3,24). In this epigenetic study, we investigated genome-wide DNA methylation and histologic subtypes using fresh frozen DNA from 485 ovarian cancer tumors, using Illumina HumanMethylation450 BeadChips (over 440 000 CpG sites following exclusions). We identified eight ovarian cancer methylation classes based on the semi-supervised RPMM analyses, one of which, termed RRL, was enriched for clear-cell cases. This is the most comprehensive ovarian cancer tumor epigenetic study to date. There are a number of studies in the literature reporting methylation in ovarian cancer and ovarian cancer cell lines (15,16,25–27), and methylation differences in ovarian cancer versus normal tissue (28–30), but sample sizes were often small and comparison across subtypes was rarely done (15), especially with a high-coverage methylation array. The TCGA reported 168 genes as epigenetically silenced (promoter hypermethylation associated with decreased gene expression) in high-grade serous ovarian cancer samples compared with fallopian tube controls (17); as expected, none of these were among our best 100 clear-cell differentiating CpGs. That the TCGA only examined high-grade serous ovarian tumors and examined lower density CpGs (average two CpGs per promoter) on the Illumina Infinium HumanMethylation27 BeadChip demonstrated the need for more comprehensive assessment of ovarian cancer methylation.

Human promoters containing a CpG island tend to remain nucleosome-free as well as methylation-free. However, methylation of these regions is now firmly established as an important mechanism for gene inactivation. CpG island hypermethylation of tumor-suppressor genes has been described in almost every tumor type. In contrast, exons demonstrate a high degree of methylation and nucleosome occupancy (31). Importantly, exonic CpG islands are more susceptible to de novo methylation than promoter islands and methylation seeded in exonic regions may spread to other islands, including promoter regions (31). Furthermore, recent work has demonstrated that exonic DNA methylation seems to function together with exonic nucleosomes and H3K36me3 for the proper splicing of transcripts with different expression levels (31).

Because there is evidence in the literature showing importance of SWI/SNF (SWItch/Sucrose NonFermentable) genes in clear-cell tumors (1), we examined the difference in the methylation in 10 of these genes between clear-cell and non-clear-cell cases. In total, there were 264 CpGs that passed our QC, which were associated with MTOR, ARID1A, PIK3CA, PTEN, CHD4, TP53, HNF1B, PPMD1D, PPP2R1A and EP300. We first implemented a series of locus-by-locus analyses for examining the association between the methylation of these 264 CpGs and clear-cell histology. As before, these models were controlled for age, stage, grade, ascites and peritoneal cytology. Our results showed that for both the training set and replication set 1, there did not appear to be any strong relationship between the methylation of these 264 CpGs and clear-cell histology, as evidenced by their uniform distribution of P-values. For the combined analysis, there was a slight trend toward non-uniformly distributed P-values, with heavier weight toward lower P-values; however, the strength of association for these 264 CpGs was considerably less than the top 100 CpGs identified in our previous analysis. Along these lines, among these 264 CpGs, none appeared in our list of the top 1000 CpGs that associate with clear-cell histology. Thus, our agnostic examination identified probes that are much more strongly associated with clear-cell histology than any of the probes associated with the SWI/SNF genes.

In addition to molecular profiling of clear-cell ovarian cancer cases, we classified the 54 genes which included the top 100 CpGs differentially methylated in clear cell using Ingenuity Pathway Analysis (IPA). These genes were correlated in the human interactome by evidencing the functional networks. Clear-cell-specific differentially methylated genes were found to be involved in various molecular and cellular functions and most specifically, 19 genes including KCNH2 in ‘Cell Cycle, Cellular Development, Cell Death’. KCNH2 methylation and expression are the most consistently associated, suggesting that investigation of its role may shed light on the biology of clear-cell ovarian cancer. The KCNH2 gene region was also evaluated as an example to show that even when considering a broader region (± 2 Mb), the same methylation signal associated with clear-cell histology was detected. This gene encodes an ether-a-go-go potassium channel in cardiac cells (32). KCNH2, also known as HERG, belongs to the Eag family, which have been implicated in signaling pathways leading to cell proliferation or apoptosis (programmed cell death) (33). Studies on ovarian and endometrial cancer cell lines have shown preferential expression of HERG in tumor cell lines, and high expression was correlated with cell proliferation (34,35). Furthermore, K+ channel blockers, 4-AP and TEA, have been reported to significantly inhibit the proliferation of HERG-positive SKOV-3 cells (36). EAG (Kv10.1) overexpression in ovarian cancer was associated with poor prognosis, identifying it as a therapeutic target. KCNH2 (Kv11.1, HERG) is also reported to be overexpressed in ovarian cancer. Of the 25 clear-cell cancers identified in that report, 17 had lower levels of Eag expression. Their study did not specifically highlight the expression levels of HERG in clear-cell tumors. However, based on our data, we speculate that loss of expression of KCNH2 (HERG) by methylation could be a good prognostic marker, given that overexpression of the Eag family members promoted increased proliferation and results in poor prognosis.

A number of factors strengthen our study. The number of tumors assessed (n = 485), the use of fresh frozen tumor material, the inclusion of technical validation and the validation of the profile in two additional independent ovarian tumor case collections give us confidence in our results. Even though the number of clear-cell cases was small (n = 30), we were able to validate the clear-cell-specific methylation profile in two replication sets. It was also advantageous to have consistent pathology review and sample handling for all samples. Compared with conventional unsupervised analytical methods, the approach we used, SS- RPMM, also provided some strengths. We incorporated phenotype information into the learning of clustering patterns, and prevented data over-fitting through nested cross-validations. This enabled automatic selection of optimal cluster number, M, which is usually difficult to determine for non-parametric methods, such as K-mean and hierarchical clustering. Since logit-transformed methylation beta values are approximately Gaussian-distributed, model-based RPMM is also
expected to be more robust to outliers and powerful to detect underlying data structures than distribution-free clustering approaches. Nonetheless, we note that a limitation of SS-RPMM and all clustering methods is that they are mainly driven by data measurement; as a result, they could not incorporate biological context, such as interactions among genes and coordination of molecular functions. Also, optimality of the numerical model is conditional on statistical assumptions, some of which may not be valid for genomic data.

In conclusion, this study provides a comprehensive analysis of ovarian tumor DNA methylation and demonstrates that methylation in clear-cell ovarian cancer is distinct from other ovarian cancer histologies. Ovarian clear-cell carcinoma is a distinct histopathologic subtype of EOC with an incidence of 5–10% of all ovarian malignancies, and the small sample size (6.2%) in our study is within the expected range of incidence. However, our findings should be interpreted with caution, and validation in a larger cohort of clear-cell tumors of the ovary is warranted.

MATERIALS AND METHODS

Eligible cases were women aged ≥20 years who were ascertained between 1992 and 2009 at the Mayo Clinic within 1 year of diagnosis with pathologically confirmed primary invasive epithelial ovarian, fallopian tube or primary peritoneal cancer. Borderline and non-EOC cases were excluded. Participants were split into three approximately equally sized collections representing a training set (n = 163) and two replication sets (n = 163, n = 159; Table 1). Tumors were snap-frozen immediately following surgery and stored at −80°C. The clinical diagnoses were confirmed by re-review by a gynecologic pathologist who verified histology and tumor grade. A gynecologic pathologist (D.W.V.) reviewed each tissue to ensure 70% tumor content prior to DNA extraction. Cases gave informed consent; all protocols were approved by the Mayo Clinic Institutional Review Board.

Methylation arrays

Samples from the training set and the first replication set were assayed and underwent combined quality control procedures at the Mayo Clinic Molecular Genome Facility (Rochester, MN, USA); the second replication set was analyzed at Illumina Corporation (San Diego, CA, USA). Tumor DNA (1 µg at Mayo Clinic, and 250 ng at Illumina) was bisulfite-modified (BSM) using the Zymo EZ96 DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer’s protocol. Methylation analyses used the Illumina Infinium HumanMethylation450 BeadChip, which interrogates more than 485 000 CpG loci across the genome (37,38), following the manufacturer’s protocol using 250 ng (Mayo Clinic) or 160 ng (Illumina) of BSM DNA. At the Mayo Clinic, BSM-negative and +positive controls were also included (n = 9 and n = 16, respectively), as were Centre d’Etudes du Poly-morphismes Humain (CEPH) DNA replicates (n = 9), and samples were run in two batches. Briefly, fragmented DNA was hybridized to BeadChips, which were then processed through a primer extension and an immunohistochemistry staining protocol to allow detection of a single-base extension reaction. Finally, BeadChips were coated and then imaged on an Illumina iScan. Analysis included control probes for assessing sample-independent and sample-dependent performance. The methylation level of each CpG locus was calculated in GenomeStudio® Methylation module (v.1.9.0). The methylation status of the target CpG sites was determined by comparing the ratio of fluorescent signal from the methylated allele with the sum from the fluorescent signal from both methylated and unmethylated alleles. The two replication sets had 32 samples in common and were used to validate performance of the methylation assays at two different institutions. Intraclass correlation of beta values for each sample that was run at both laboratories was estimated. Each intraclass correlation coefficient was >0.85 (data not shown). One set of the duplicate samples was taken out from replication set 2 for further analysis.

Technical validation

Nine CpGs with a broad spectrum of percent methylation (range 0.23–0.78) and relatively high variability (standard deviation 0.13–0.36) were also assessed using bisulfite Pyrosequencing. Ninety-five samples were tested, including 35 samples that had been run on BeadChips at the Mayo Clinic, 24 samples that had been run on BeadChips at Illumina, 30 samples which had been inadvertently processed on BeadChips at both laboratories (removed from the second replication set for analyses), four BSM-negative controls and two BSM-positive controls (CpGenome™ Universal Methylated DNA; Millipore Corporation, Billerica, MA, USA). Primers (Supplementary Material, Table S1) were designed using the Pyrosequencing Assay Design Software. DNA (20–30 ng) was PCR-amplified using primers, one of which was biotinylated. Briefly, the incorporated biotinylated amplicon was immobilized on streptavidin-coated beads used to purify and render the denatured, single-stranded and biotinylated PCR product. The single-stranded DNA was purified using the Pyrosequencing vacuum workstation. The single-stranded product was annealed to 0.3 µM of the sequencing primer complementary to the single-stranded template and placed at 85°C for 2 min and then cooled to room temperature for 5 min. Pyrosequencing reactions were performed on Biotage PyroMark MD, and data were analyzed using the PyroMD Software. Percent methylation was quantified as methylated C-to-unmethylated C ratio using the Pyro Q-CpG software, which analyzes 96 samples and provides automatic quality control for each sample for the completion of bisulfite conversion and estimates of non-converted DNA. Results suggested that BeadChip data were satisfactory; the median Pearson correlation of methylation values between BeadChip and Pyrosequencing assays was 0.84 for Mayo Clinic and 0.87 for Illumina (Supplementary Material, Table S1).

Methylation data pre-processing

Using the Illumina GenomeStudio software, DNA methylation values from BeadChip assays were scored as beta values, ranging from 0 (unmethylated) to 1 (methylated). Probes which had a reference SNP id or were positioned at a single-nucleotide polymorphism (dbSNP build 137), which had high
beta values in BSM-negative controls (beyond 4 standard deviations of mean) or which were detected in <70% of samples were excluded. A total of 440 649 and 448 543 Illumina probes passed quality control in training set/repli-
cation set 1 and replication set 2, respectively (Supplementary Mat-
terial, Table S2). The intraclass correlation for beta values among
CEPH replicates at training and replication set 1 was 0.99 and
that for tumor duplicate samples was >0.99. We removed
samples that failed or were from cases who had received
neoadjuvant chemotherapy. Within each batch, based on an
observed plate effect, a correction was applied by fitting a
linear model with fixed plate effect for each logit-transformed
CpG locus with the unstandardized residual saved. The logit-
transformed locus mean was added back onto the residual
before back-transforming the value to a 0–1 scale. To adjust
for batch effects, we used the COMBAT methodology,
which has recently been shown to perform effectively and ef-
ciently compared with other batch-adjustment methodologies
(39); briefly, this involved a location (mean) and scale (vari-
ance) adjustment using an empirical Bayes framework (40).

Methylation clustering

The scheme of our analysis strategy aimed at identifying and
validating novel epigenetic biomarkers of clear-cell ovarian
cancer is depicted in Supplementary Material, Figure S5. We used SS-RPMM to determine methylation profiles that
are associated with clear-cell histology (41). Using the training
set, linear models were fit to each of the CpG loci separately to
examine the association between logit-transformed methyla-
tion (42) and clear-cell histology. CpG loci were then
ranked based on their strength of association with clear-cell
histology, and the top M CpG loci were selected for subse-
cquent clustering analysis; M, the optimal number of CpG
loci, was selected using a nested cross-validation procedure
(Supplementary Material, Figure S1).

Clustering of cases was achieved using the RPMM (43), a
hierarchical model-based method for clustering that has been
extensively used for the clustering of array-based methylation
data (41,44–46). Briefly, RPMM begins by comparing the
model goodness-of-fit between one-class and two-class
mixture models. If the two-class model fits the data better,
these classes are further split into two new classes and compared
with the previous split in terms of model goodness-of-fit. Recur-
sion continues until the algorithm arrives at the most parsimony-
ous representation of the data, resulting in an estimate of the
number of clusters, as well as the class membership probabil-
ities for each subject. Because of the hierarchical nature of
RPMM, classes are referred to in terms of their position on a
tree dendrogram. Thus, the class labels for the two-class
RPMM solution would be referred to as R and L, representing
the right (R) and left (L) branches of the tree, respectively. Su-
ccessive branches of the tree follow the same nomenclature,
wherein the label for each child node is preceded by the label
for the respective parent node. Based on the RPMM fit to the
training data, a naive Bayes classifier, a probabilistic
classifier, was used to predict methylation class membership
for the observations in each of the two independent replication
set. Subjects were then assigned to the class with the highest
membership probability. All models were adjusted for subject
age, stage, grade, peritoneal cytology and ascites, as these po-
tential confounding factors were found to be associated with
histology.

The association between the predicted methylation classes in
the replication sets and clear-cell histology was assessed using
permutation chi-square tests and unconditional logistic regres-
sion models. In addition, for the top M (22) CpGs, the difference
in methylation between clear-cell and non-clear-cell histology
was tested in the independent replication sets using a non-
parametric Wilcoxon rank-sum test. In addition, an exploratory
analysis examined the clinical outcome of the RRL methylation
class (consisting primarily, but not exclusively, of clear-cell
cases). Specifically, we examined survival in clear-cell cases
versus others and in RRL-assigned cases versus others by plot-
ting Kaplan–Meier curves using all data (n = 485), accounting
for left truncation and right censoring at 10 years of follow-up.
The follow-up for all cases was right-censored at 10 years in an
attempt to minimize the number of non-ovarian deaths in our
analysis.

Preliminary analyses were unadjusted for potential confound-
ers; analyses were carried out using R version 2.13 (www.cra
n.r-project.org).

Gene expression analyses

For the top M (22) CpGs, analyses of mRNA expression at
relevant genes were also performed. Tumor RNA was isolated
from 171 fresh frozen samples using the Qiagen RNEasy
protocol and quantitated using a Nanodrop Spectrophotomer
(Agilent Technologies, Santa Clara, CA, USA). An amount
of 750 ng of high-quality total RNA with RNA integrity
numbers >8.0 was labeled with cyanine 5-CTP or cyanine
3-CTP, using the Low RNA Input Fluorescent Linear Ampli-
fication Kit (Agilent Technologies), purified on RNeasy Mini
columns (Qiagen) and hybridized to Agilent whole human
genome 4×44K expression arrays (using a mixed reference of
107 tumor samples including 63% serous, 5% endome-
trioid, 3% mucinous, 3% clear cell). Slides were scanned
using the Agilent 2565BA Scanner, and data were exported
by the Agilent Feature Extraction Software (version 7.5.1)
and transferred into the Rosetta Resolver software (Rosetta
Inpharmatics LLC, WA, USA) for further analysis. Gene ex-
pression data in the form of log2 ratios of signal from individ-
ual tumor to signal from the reference mix were used for
analysis. The intensity ratios between the tumor sample and
mixed reference calculated for each sequence were computed
according to the Agilent error model. For each CpG locus of
interest within a gene, we assessed the association of mRNA
expression at the corresponding gene with DNA methylation
beta values using Spearman’s correlations. We tested the dif-
ference in methylation between clear-cell and non-clear-cell
cases, using a non-parametric Wilcoxon rank-sum test.

Pathway analysis

The relationships between the genes of interest were investi-
ingenuity.com). The robustness of our clustering allowed us
to increase the number of CpG loci from optimal M (22) to
100 that best discriminated of clear-cell histology. This was
achieved by ranking the CpGs based on their strength of association with clear-cell histology and selecting the top 100 on the basis of their $P$-value. Although our SS-RPMM analysis used the top 22 CpGs for the generation of methylation profiles, the top 100 CpGs were selected for our pathway analysis, which are associated with 54 unique genes, which provided us with a larger pool of genes for identifying biologically informative pathways. It is also important to note that the methylation profiles ascertained using the top 22 CpGs versus the top 100 were highly consistent, giving us confidence in using the 54 genes associated with the top 100 CpGs. As a result, these 54 genes were used in our pathway analysis, allowing us to gain further insight into the molecular functions of genes associated with differentially methylated CpGs. The aim was to examine whether any biological pathway was over-represented among these genes using a broad functional enrichment analysis with Fisher’s exact testing, and to identify and visualize specific networks modeling the molecular relationships of these genes.

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.

Conflict of Interest statement. None declared.

FUNDING
This work was supported by the National Institutes of Health (R01 CA122443 to E.L.G., P50-CA136393 to Mayo Clinic Spore Ovarian Cancer, E.L.G.) and the Fred C. and Katherine B. Andersen Foundation (Women’s Cancers: Improving Care through Genomics to E.L.G.).

REFERENCES


